Markets · 1 sources covering this

European Stocks Trim Monthly Gain as Novo Nordisk and UMG Slump

European shares pared some of their Friday gains as a decline on Novo Nordisk A/S weighed on the market, countering a rally in tech stocks and another round of largely upbeat results.

Share:X WhatsApp Reddit Facebook LinkedIn Open ↗

Coverage spectrum

1 L · 0 C · 0 R

How 1 sources are covering this

BloombergLean L·7h ago
European Stocks Trim Monthly Gain as Novo Nordisk and UMG Slump
European shares pared some of their Friday gains as a decline on Novo Nordisk A/S weighed on the market, countering a rally in tech stocks and another round of largely upbeat results.
Read at Bloomberg →

Embed this bias spectrum on your site

Paste this iframe wherever you'd like the widget to appear. Resizes responsively; no JS required.

<iframe
  src="https://statesidedaily.com/embed/cluster/4b58b5160efeea6a2805524beee3e4bdfa6e13a8"
  width="100%" height="320"
  style="border:0;max-width:680px"
  loading="lazy"
  title="European Stocks Trim Monthly Gain as Novo Nordisk and UMG Slump"></iframe>

European Stocks Trim Monthly Gain as Novo Nordisk and UMG Slump

How 1 sources are covering this

European Stocks Trim Monthly Gain as Novo Nordisk and UMG Slump

More from Markets

Novo Nordisk’s stock slumps after failed trial — adding to the company’s woes

Apple heads for $460 billion wipeout with its stock seeing worst post-earnings drop in 13 years

Situational Awareness Losses Raise AI Fears

Why 3 Fed dissenters say waiting to raise interest rates could make inflation harder to tame

Reader

Trust & legal

Across the network

How 1 sources are covering this

European Stocks Trim Monthly Gain as Novo Nordisk and UMG Slump

More from Markets

Novo Nordisk&#x2019;s stock slumps after failed trial &#x2014; adding to the company&#x2019;s woes

Apple heads for $460 billion wipeout with its stock seeing worst post-earnings drop in 13 years

Situational Awareness Losses Raise AI Fears

Why 3 Fed dissenters say waiting to raise interest rates could make inflation harder to tame

Reader

Trust & legal

Across the network

Novo Nordisk’s stock slumps after failed trial — adding to the company’s woes